We agree with the reviewer that breast cancer is a heterogenous disease and we should show subtype-specific data. We analyzed survival outcomes and the cell fraction in TME by each immunohistological subtype. We did not observe any validated difference in survival outcomes. Cell fractionation of immune cells and stromal cells showed almost similar trends for the scores such as intratumor heterogeneity, HRD, mutation rate, and neoantigens across all subtypes. The results for each immunohistological subtype of single-cell Cohort 2 are shown in Supplementary Figure 7, and each subtype showed the same trend. We have revised the results section and added supplementary data as follows.
Aguirre-Ghiso group recently demonstrated that NR2F1 agonist treatment induced cancer cell dormancy [21], which raised an expectation that NR2F1 expression in primary breast cancer may have the possibility to be a biomarker.